文献速递乳腺癌

大分割对比常规分割乳房切除术后放疗联合内乳淋巴结照射治疗高危乳腺癌的III期随机试验

Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial.
PubMed 文献 · J Clin Oncol · 2026-10-19

HypoMast-IMNI 是一项III期非劣效随机试验,纳入1494例高危可手术乳腺癌术后患者,随机接受大分割放疗(42.56 Gy/16次)或常规分割放疗(50 Gy/25次),均照射胸壁及包括内乳淋巴结的区域淋巴结。

要点

  • 高危乳腺癌术后需内乳淋巴结照射时,大分割放疗局部区域控制非劣于常规分割。
  • 大分割组3级急性皮肤毒性显著低于常规分割组(1.7% vs 12.2%)。
  • 两组≥2级放射性肺炎及肺纤维化发生率均低且相当,未记录缺血性心脏事件。

核心结论

  • 对于需行乳房切除术后放疗联合内乳淋巴结照射的高危可手术乳腺癌患者,16次大分割方案在局部区域控制方面非劣于常规分割放疗,且急性毒性更优、心肺安全性良好。

研究设计与样本

  • III期非劣效随机试验,2018年9月至2022年7月随机分配1494例高危乳腺癌术后患者(1:1)至大分割放疗(42.56 Gy/16次)或常规分割放疗(50 Gy/25次),均照射胸壁及包括内乳淋巴结的区域淋巴结。
  • 主要终点为局部区域复发,次要终点包括无远处转移生存、乳腺癌无复发生存、无病生存、总生存及治疗相关毒性;改良意向治疗人群n=1429,中位随访58.1个月。

主要发现

  • 5年无远处转移生存、乳腺癌无复发生存、无病生存及总生存两组间均无显著差异。
  • ≥2级放射性肺炎及肺纤维化发生率低且两组相当,未记录缺血性心脏事件。

关键数值与推荐

  • 大分割方案:42.56 Gy分16次;常规分割方案:50 Gy分25次;均照射胸壁及区域淋巴结包括内乳淋巴结。
  • 入组高危定义包括pT1-4N2-3、pT3-4N1或pT1-2N1伴其他高危因素。

临床怎么用

  • 高危乳腺癌乳房切除术后需内乳淋巴结照射时,可考虑采用42.56 Gy/16次的大分割方案替代50 Gy/25次常规分割。
  • 大分割方案可显著降低3级急性皮肤毒性,且心肺安全性良好,支持其临床推广应用。

局限性

  • 原文摘要未报告非劣效界值及样本量估算细节。
  • 中位随访58.1个月,长期心脏毒性及晚期肺毒性数据尚待进一步随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: When coverage of internal mammary nodes (IMN) is required, the efficacy and safety of hypofractionated regimens within postmastectomy radiotherapy (PMRT) remain to be established. This study evaluated hypofractionated radiotherapy (HypoRT) in patients with high-risk, operable breast cancer undergoing PMRT with IMN irradiation (IMNI). METHODS: In this phase III noninferiority trial, eligible patients with high-risk disease after mastectomy (including pT1-4N2-3, pT3-4N1, or pT1-2N1 disease with additional high-risk factors) were randomly assigned (1:1) to HypoRT (42.56 Gy in 16 fractions) or conventionally fractionated radiotherapy (ConvRT; 50 Gy in 25 fractions), both targeting the chest wall and regional lymph nodes, including the IMN. The primary end point was locoregional recurrence (LRR). Secondary end points were distant metastasis-free survival (DMFS), breast cancer recurrence-free survival (BCRFS), disease-free survival (DFS), overall survival (OS), and treatment-related toxicity. The trial is registered with ClinicalTrial.gov (identifier: NCT03856372). RESULTS: Between September 2018 and July 2022, 1,494 patients were randomly assigned. After a median follow-up of 58.1 months in the modified intention-to-treat population (n = 1,429), the 5-year cumulative incidence of LRR was 1.7% (95% CI, 0.9 to 2.9) with HypoRT and 2.2% (95% CI, 1.3 to 3.5) with ConvRT (hazard ratio, 0.69 [95% CI, 0.32 to 1.51]), meeting the noninferiority criterion (P = .017). No significant differences were observed in 5-year DMFS, BCRFS, DFS, or OS. Grade 3 acute skin toxicity was significantly lower with HypoRT (1.7% v 12.2%, P < .001). The incidence of grade ≥2 radiation pneumonitis and pulmonary fibrosis was low and comparable between arms, with no ischemic cardiac events recorded. CONCLUSION: For patients with high-risk, operable breast cancer requiring PMRT with IMNI, the 16-fraction HypoRT regimen is noninferior to ConvRT for locoregional control, offers a superior acute toxicity profile, and demonstrates excellent cardiopulmonary safety.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wang X, Zhang X, Chen X, et al. Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial. J Clin Oncol. 2026. PMID: 42896129. doi:10.1200/JCO-25-02843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。